Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
about
Current and emerging treatment options for patients with relapsed myelomaChemotherapy-induced peripheral neurotoxicity: a critical analysisTreatment of multiple myeloma bone disease: experimental and clinical data.European perspective on multiple myeloma treatment strategies: update following recent congressesGuidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012Choosing treatment options for patients with relapsed/refractory multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Current therapeutic strategies for multiple myeloma.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Chemotherapy-Related Neurotoxicity.Pomalidomide in the treatment of relapsed multiple myeloma.Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma.The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma.Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
P2860
Q26830878-049BFD7B-2DEF-466F-B0A7-5C3F44B5F3CEQ27010318-7101EB32-BAEA-4A20-837F-C81EA886BC60Q30868833-05096F63-5A51-4C40-8B23-D5FAD9DCF694Q35989943-E3379F44-FC10-4984-8D07-017F6D1E26BDQ37057028-2FFB9F35-7717-4C3E-A98E-D714D02FAC2AQ38170453-2641D9EA-09BA-4EB3-A195-1E73250C92DAQ38261677-DABF7D45-72EB-4AE9-B617-D830FDC6F46FQ38412189-8DFB4163-DB2B-4EAC-8706-DB04AD905861Q38630472-35965EE0-9E87-4360-A1FC-5C874970D9B7Q38672091-B3811FE2-5ECD-403B-99F1-F28C24AD49EDQ38904676-DA230EB8-6659-4A02-8847-E8AC05451750Q39388200-1E07A83B-5D17-4A58-8560-2A9B08FD66ECQ39584752-9723667F-9CEB-41F8-8B04-447CCEA55D26Q45245750-1524974B-73E7-46CE-8FD6-0BC3165F4EC7Q51795374-529B32A5-BC76-4C7C-851F-E49B68C264EDQ53543459-910DD9A9-CF50-4F92-9D66-3883CF19EAFCQ55513961-09F65C2E-261E-41A2-8E0D-E9F314FEDF1FQ58729834-5A15E8B9-627A-4291-916B-67F65A3104AB
P2860
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Thalidomide versus dexamethaso ...... m OPTIMUM, a randomized trial.
@ast
Thalidomide versus dexamethaso ...... m OPTIMUM, a randomized trial.
@en
type
label
Thalidomide versus dexamethaso ...... m OPTIMUM, a randomized trial.
@ast
Thalidomide versus dexamethaso ...... m OPTIMUM, a randomized trial.
@en
prefLabel
Thalidomide versus dexamethaso ...... m OPTIMUM, a randomized trial.
@ast
Thalidomide versus dexamethaso ...... m OPTIMUM, a randomized trial.
@en
P2093
P2860
P50
P1433
P1476
Thalidomide versus dexamethaso ...... m OPTIMUM, a randomized trial.
@en
P2093
Axel Glasmacher
Claire Pattou
Elisabeth Kueenburg
Honorata Giongco Baylon
Jens Hillengass
Joan Bladé
Martin Kropff
Peter Liebisch
Robert Zerbib
P2860
P304
P356
10.3324/HAEMATOL.2011.044271
P577
2011-12-01T00:00:00Z